Russell E. Lewis mainly focuses on Microbiology, Internal medicine, Mycosis, Aspergillosis and Caspofungin. His work in Microbiology tackles topics such as Virulence which are related to areas like Drosophila melanogaster and Melanogaster. His Internal medicine study combines topics from a wide range of disciplines, such as Voriconazole and Surgery.
His research investigates the connection between Mycosis and topics such as Zygomycosis that intersect with problems in Odds ratio. His Aspergillosis research is multidisciplinary, relying on both Amphotericin B and Posaconazole. His research in Caspofungin intersects with topics in Biological activity, In vitro, Pharmacology and Calcineurin.
His scientific interests lie mostly in Microbiology, Internal medicine, Aspergillosis, Amphotericin B and Immunology. In his research, Mutant and Drosophila melanogaster is intimately related to Virulence, which falls under the overarching field of Microbiology. His Internal medicine research includes themes of Gastroenterology and Surgery.
His Aspergillosis research incorporates elements of Cancer, Mycosis, In vivo and Intensive care medicine. His Mycosis research integrates issues from Respiratory disease, Lung, Zygomycosis and Pathology. Russell E. Lewis works mostly in the field of Amphotericin B, limiting it down to topics relating to Pharmacology and, in certain cases, Caspofungin, as a part of the same area of interest.
His primary areas of study are Internal medicine, Microbiology, Intensive care medicine, Voriconazole and Disease. While the research belongs to areas of Internal medicine, Russell E. Lewis spends his time largely on the problem of Gastroenterology, intersecting his research to questions surrounding Pharmacodynamics, Continuous infusion and Beta lactam antibiotics. His Microbiology study combines topics in areas such as Bacterial protein, Immune system and Virulence.
He interconnects Pharmacokinetics, Hematopoietic stem cell transplantation, Epidemiology, MEDLINE and Retrospective cohort study in the investigation of issues within Intensive care medicine. His Voriconazole study integrates concerns from other disciplines, such as Hematology, Echinocandin, Aspergillosis and Intensive care unit. His studies in Aspergillosis integrate themes in fields like Aspergillus fumigatus, Mucorales and Immunosuppression.
Russell E. Lewis mainly investigates Internal medicine, Intensive care medicine, Voriconazole, Aspergillosis and Posaconazole. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Surgery and Colistin. His Intensive care medicine study combines topics from a wide range of disciplines, such as Pharmacokinetics, Pharmacodynamics, Epidemiology, Disease and Acute kidney injury.
The Aspergillosis study combines topics in areas such as Aspergillus fumigatus and Surveillance study. The concepts of his Posaconazole study are interwoven with issues in Azole, Disease management, Aspergillus and Transplantation. His work in Aspergillus addresses issues such as Aspergillus terreus, which are connected to fields such as Amphotericin B.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Zygomycosis in a Tertiary-Care Cancer Center in the Era of Aspergillus-Active Antifungal Therapy: A Case-Control Observational Study of 27 Recent Cases
Dimitrios P Kontoyiannis;Michail S. Lionakis;Russell E. Lewis;Russell E. Lewis;Georgios Chamilos.
The Journal of Infectious Diseases (2005)
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
Georgios Chamilos;Mario Luna;Russell E. Lewis;Russell E. Lewis;Gerald P. Bodey.
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
A. J. Ullmann;J. M. Aguado;S. Arikan-Akdagli;D. W. Denning.
Clinical Microbiology and Infection (2018)
Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis
Georgios Chamilos;Russell E. Lewis;Russell E. Lewis;Dimitrios P. Kontoyiannis.
Clinical Infectious Diseases (2008)
Antifungal drug resistance of pathogenic fungi
Dimitrios P Kontoyiannis;Russell E Lewis.
The Lancet (2002)
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study
Nina Singh;Nina Singh;Ajit P. Limaye;Graeme Forrest;Nasia Safdar.
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies
Dimitrios P Kontoyiannis;Ray Y Hachem;Russell E. Lewis;Gustavo A. Rivero.
Pharmacology of Systemic Antifungal Agents
Elizabeth S. Dodds Ashley;Elizabeth S. Dodds Ashley;Russell Lewis;Russell Lewis;James S. Lewis;James S. Lewis;Craig Martin.
Clinical Infectious Diseases (2006)
Current Concepts in Antifungal Pharmacology
Russell E. Lewis.
Mayo Clinic Proceedings (2011)
Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer.
Georgios Chamilos;Edith M. Marom;Russell E. Lewis;Michail S. Lionakis.
Clinical Infectious Diseases (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: